• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance

Merck Rises, Bristol-Myers Slides Following Cancer Meeting

By Kurt Osterberg · On April 16, 2018

Shares of Merck (MRK) are rising this morning, while peer Bristol-Myers (BMY) is sliding, after both companies presented new data on their respective cancer immunotherapy treatments at the American Association for Cancer Research annual meeting that began over this weekend.

MERCK’S KEYTRUDA: In conjunction with the AACR meeting, Merck announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with pemetrexed, or ALIMTA, and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer. The addition of Keytruda to pemetrexed plus platinum chemotherapy achieved a significant improvement in progression-free survival, or PFS, with a reduction in the risk of progression or death of nearly half for patients in the KEYTRUDA combination arm, compared with chemotherapy alone, Merck stated.

BRISTOL’S OPDIVO: Meanwhile, Bristol-Myers Squibb announced initial results from the pivotal Phase 3 study, CheckMate -227, evaluating the Opdivo 3 mg/kg plus low-dose Yervoy combination in first-line advanced non-small cell lung cancer patients with high tumor mutational burden greater than or equal to10 mutations/megabase. In the Phase 3 CheckMate -227 trial, Opdivo plus low-dose Yervoy reduced the risk of progression or death by 42% versus chemotherapy in first-line lung cancer patients with high tumor mutational burden. The one-year progression-free survival rate was more than triple with the combination versus chemotherapy, or 43% vs. 13%, in first-line non-small cell lung cancer patients with high TMB greater than or equal to10 mut/Mb, the company stated.

PRICE ACTION: In early trading, Merck shares have gained $1.79, or 3%, to $58.97 while Bristol-Myers shares have fallen over 5% to $55.50.
 

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    How To Earn A 10% Yield On Cost From PepsiCo Dividends

  • Finance

    Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus

  • Finance

    How To Trade Options

Top Finance

  • Samsung Galaxy Note 9 Review Samsung Galaxy Note 9 Review
  • Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates
  • Hey, Sand Hill Exchange. Shouting 'blockchain!' won't stop the Feds Hey, Sand Hill Exchange. Shouting ‘blockchain!’ won’t stop the Feds
  • Nike's Kaepernick Ad Has Cost The Company Over $3 Billion So Far Nike’s Kaepernick Ad Has Cost The Company Over $3 Billion So Far
  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce

New Posts

  • How To Earn A 10% Yield On Cost From PepsiCo Dividends

    How To Earn A 10% Yield On Cost From PepsiCo Dividends

    October 21, 2018
  • Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus

    Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus

    October 21, 2018
  • How To Trade Options

    How To Trade Options

    October 21, 2018
  • Adding To Merkel’s Woes: SPD’s Collapse In Germany, Greens The New Left Darlings

    Adding To Merkel’s Woes: SPD’s Collapse In Germany, Greens The New Left Darlings

    October 20, 2018
  • Self Sufficiency Over Adversity

    Self Sufficiency Over Adversity

    October 20, 2018
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018 NJCEE. All Rights Reserved.